Crizotinib
Reading tools
Crizotinib (Xalkori®), which received FDA approval on 11 March 2016, is used in patients with disease spread to distant tissues (metastatic), with a ROS-1 mutation, and non-small cell lung cancer . It also received approval in 2011 for use in patients with ALK-positive lung cancer.
It exerts its effect through the molecule called ALK, involved in cell proliferation and tumor cell formation. Inhibiting ALK function prevents tumor cell formation and growth. The most common side effects of Crizotinib include nausea, fatigue, vomiting, blurred vision and sensitivity to light.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.